SI
SI
discoversearch

Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2148 94 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2148<MZ- Any reason you can see for the roller coaster this week?> Jim, firsMiljenko Zuanic-yesterday
2147MZ- Any reason you can see for the roller coaster this week?Biotech Jim-yesterday
2146Also, keep in mind that REGN is working on PEG-Afliber formulation, but here I qMiljenko Zuanic-Tuesday
2145ARVO 2017: arvo.org P# A0087.....overal, ~50% pts were on > or = Q12W, secoMiljenko Zuanic-Tuesday
2144yan mentioned several time in last two Q-cc. Everyone knows, but pretend "bMiljenko Zuanic-Tuesday
2143Curious why it's up, all the analysts seem to think this is a win for NovartFelix B-Tuesday
2142novartis.com Not extraordinary, so far nothing BETTER, in the RTH258 results, aMiljenko Zuanic-Tuesday
2141Ahhhh I meant fast trak the entire time, I can't keep track of all these FDAFelix B-Sunday
2140When did Tanezumab receive Breakthrough designation? It has fast track, which isMiljenko Zuanic-Sunday
2139So how can one get breakthrough and not the other is what I am asking? You woulFelix B-Sunday
2138It is a good article from ICER-corner, still missing deeper analysis of the drugMiljenko Zuanic-June 15
2137They are not, I am talking about class compounds.Miljenko Zuanic-June 15
2136How are they different?Felix B-June 15
2135While Tanezumab and Fasinumab are active with novel mode of action, side effectMiljenko Zuanic-June 15
2134Why? Breakthrough has been designated before to multiple drugs with same targetFelix B-June 15
2133<Safe to assume REGN will get breakthrough status as well?> I think it iMiljenko Zuanic-June 15
2132Safe to assume REGN will get breakthrough status as well? Is it possible to seeFelix B-June 14
2131Seams that Abs-manufacturing will be kay point in next few years. Too bad, SanofMiljenko Zuanic-June 14
2130Probably, .. seekingalpha.comMiljenko Zuanic-June 14
2129Does anyone has pass for Goldman Sachs investor conference , @ Rancho Palos VerdMiljenko Zuanic-June 8
2128Was just going to post this and ya beat me to it...Felix B-June 8
2127Is this sarilumab PROBLEM too???? (ACTEMRA): statnews.com rxlist.com Label for Miljenko Zuanic-June 7
2126Means that as of cut-off date more than 1/2 subjects still receive treatment andMiljenko Zuanic-June 6
2125Question on the recent REGN2810 release: "Median progression-free survivalFelix B-June 6
2124<But is the court so foresightful?> IF they are not, Pandora box is openMiljenko Zuanic-June 6
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.